Helsinn ANAM-17-20

A phase 3, randomized, double-blind, placebocontrolled, multicenter study


Helsinn ANAM-17-20


Multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of anamorelin HCl. Approximately 316 patients with advanced NSCLC with cachexia will be randomized 1:1 to anamorelin HCl 100 mg or placebo, taken orally once daily (QD) for a total of 24 weeks. Patients will be instructed to take the study drug at least 1 hour before their first meal of the day.



Florida East Coast-Jacksonville
Maddie Hamilton